To make sure people trust the vaccines, we need a very transparent process.
Show Notes
Antibodies, convalescent plasma, gene-based vaccines — you may have heard these terms on the evening news, but what do they mean? How might they help in the battle against Covid-19? As the race to develop a vaccine continues, questions remain about effectiveness, testing, and whether people will actually get the vaccine once it’s on the market. Two medical experts involved in the fight explain the science behind developing effective protection. Judith Aberg is Chief of the Division of Infectious Diseases for Mount Sinai Health System. She’s leading Mount Sinai’s Covid-19 treatment guidelines and the hospital’s clinical trials unit. Florian Krammer is a professor of vaccinology at the Icahn School of Medicine at Mount Sinai. Kenneth L. Davis, president and CEO of Mount Sinai Health System, leads the conversation. Davis is a trustee of the Aspen Institute.
This conversation was presented by Aspen Ideas: Health in September. It was part of their 20/20 series of virtual conversations.
As a 501(c)(3) nonprofit organization, the Aspen Institute is nonpartisan and does not endorse, support, or oppose political candidates or parties. Further, the views and opinions of our guests and speakers do not necessarily reflect those of the Aspen Institute.
Learn More
Additional Information
Explore
Related episodes
Disinformation online is on the minds of voters, candidates, government officials, and technology platforms as the US election gets closer. Already experts have seen disinformation campaigns around the Covid-19 pandemic, which could spell trouble in November.
The time we’re living in is unusually tumultuous. The Covid-19 pandemic is causing loss, disruption, illness, grief, anxiety, and uncertainty.
Black people are 3.5 times more likely to die of the coronavirus than white people. Why is this?
